The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis

New England Journal of Medicine

Volumn 338, Issue 2, 1998, Pages 86-93

  Kuivenhoven, Jan Albert ^a   Jukema, J Wouter ^b   Zwinderman, Aeilko H ^b   De Knijff, Peter ^b   Mcpherson, Ruth ^c   Bruschke, Albert V G ^b,d   Lie, Kong I ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DNA POLYMORPHISM; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPROTEINS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PRAVASTATIN; PROSPECTIVE STUDIES;

EID: 0032495541     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199801083380203     Document Type: Article

References (39)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
3. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
4. Kreisberg RA. Cholesterol-lowering and coronary atherosclerosis: good news and bad news. Am J Med 1996;101:455-8.
5. Yen FT, Deckelbaum RJ, Mann CJ, Marcel YL, Milne RW, Tall AR. Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody: effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. J Clin Invest 1989;83:2018-24.
6. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem 1995;64:235-57.
7. Agellon LB, Walsh A, Hayek T, et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 1991;266:10796-801.
8. Hayek T, Chajek-Shaul T, Walsh A, et al. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J Clin Invest 1992;90:505-10.
9. Hannuksela ML, Liinamaa MJ, Kesäniemi YA, Savolainen MJ. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994;110:35-44.
10. McPherson R, Mann CJ, Tall AR, et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia: relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb 1991;11:797-804.
11. Kuivenhoven JA, de Knijff P, Boer JMA, et al. Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997;17:560-8.
12. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study: high-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977;1:965-8.
13. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
14. Bhatnagar D, Durrington PN, Channon KM, Prais H, Mackness MI. Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. Atherosclerosis 1993;98:25-32.
15. Föger B, Luef G, Ritsch A, et al. Relationship of high-density lipoprotein subfractions and cholesteryl ester transfer protein in plasma to carotid artery wall thickness. J Mol Med 1995;73:369-72.
16. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73-5.
17. Quinet E, Tall A, Ramakrishnan R, Rudel L. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest 1991;87:1559-66.
18. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995;96:2071-4.
19. Fielding CJ, Havel RJ. Cholesteryl ester transfer protein: friend or foe? J Clin Invest 1996;97:2687-8.
20. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-23.
21. Freeman DJ, Griffin BA, Holmes AP, et al. Regulation of plasma HDL cholesterol and subtraction distribution by genetic and environmental factors: associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb 1994;14:336-44.
22. Tamminen M, Kakko S, Kesäniemi YA, Savolainen MJ. A polymorphic site in the 3́ untranslated region of the cholesteryl ester transfer protein (CETP) gene is associated with low CETP activity. Atherosclerosis 1996; 124:237-47.
23. Bu X, Warden CH, Xia YR, et al. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci. Hum Genet 1994;93:639-48.
24. Groenemeijer BE, Hallman MD, Reymer PWA, et al. Genetic variant showing a positive interaction with β-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients: the Ser447-stop substitution in the lipoprotein lipase gene. Circulation 1997;95:2628-35.
25. EGRET: state-of-the-art epidemiological computing: reference manual addendum for version 1. Seattle: Statistical and Epidemiological Research Corporation, 1991.
26. 9Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation 1996;94:1913-8.
27. Reymer PWA, Gagné E, Groenemeyer BE, et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995;10:28-34.
28. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76.
29. Waters D, Higginson LAJ, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
30. Drayna D, Lawn R. Multiple RFLPs at the human cholesteryl ester transfer protein (CETP) locus. Nucleic Acids Res 1987;15:4698.
31. Ahnadi CE, Berthézène F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993;99:219-28.
32. Bagdade JD, Lane JT, Stone N, Ritter MC, Subbaiah PV. Persistent abnormalities in lipoprotein composition and cholesteryl ester transfer following lovastatin treatment. J Lipid Res 1990;31:1263-9.
33. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJ. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995;44: 460-5.
34. Guerin M, Dolphin PJ, Talussot C, Gardette J, Berthezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1359-68.
35. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993;102:107-19.
36. Zambon A, Brown BG, Hokanson JE, Brunzell JD. Hepatic lipase changes predict coronary artery disease progression/regression in the Familial Atherosclerosis Treatment Study (FATS). Circulation 1996;94:Suppl I:I-539. abstract.
37. Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992;268:1429-33.
38. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-75.
39. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41.